Blood Cell Biophysical Trajectories Reveal Response to CAR-T Therapy in Diffuse Large B-Cell Lymphoma.
Although chimeric antigen receptor T-cell (CAR-T) therapy has substantially improved outcomes in diffuse large B-cell lymphoma (DLBCL), disease relapse remains a major clinical challenge. Because treatment-associated immune remodeling evolves dynamically over time, complementary biomarkers capable of longitudinally mon...